Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Markets open flat with positive bias
Fri, 26 Aug 09:30 am

Asian stock markets have opened the day on a weak note. Stock markets in Hong Kong (down 0.1%), South Korea (down 0.1%), Indonesia (down 1.1%), Nikkei (down 0.1%), and China (down 0.7%) are trading in the red. The Indian stock markets have opened the day on a flat note with a positive. Pharma stocks and software stocks are trading firm. However, stocks in the Realty space are in the red.

The BSE- Sensex is trading higher by around 22 points and the NSE- Nifty is up by around 1 point. However, midcap and small cap stocks are trading in the red, with both the BSE Midcap and BSE Small cap indices down by 0.3% and 0.2 respectively. The rupee is trading at 46.04 to the US dollar.

Pharma stocks have opened the day on a positive note with Ranbaxy and Dr Reddy leading the gains. However, Cipla is trading in the red. Pharma major, Cipla clarified that the takeover rumors floating in the market are speculative in nature and that the company has not been approached by anyone to be bought. The company has stated that the rumors of selling out are baseless. While talking about their future plans, the management said that currently Cipla has a strong field force of 7,000 medical representatives. To leverage this, they would look for marketing alliances with international companies looking to sell their products in India. The company would like to have tie-ups in the segments where Cipla is traditionally weak. This would include products in the diabetes category. The company is also looking to introduce 4 bio-similar products in next 4 years.

Power stocks have opened the day on weak note with Adani Power, JSW Energy and Suzlon Energy leading the losses. Earlier this week, the Jharkhand State Pollution Control Board (JSPCB) passed an order to close down 22 mines operated by Bharat Coking Coal Ltd (BCCL), a subsidiary of Coal India (CIL). According to JSPCB's allegations, these mines were being run without proper environmental clearances. As a result of this, CIL which accounts for over 80% of India's coal production, is set to lose about 40,000 tonnes (equivalent to 12 m tonnes annual) of coal production every day. However, the state-owned firm has it is yet to receive a closure order. Even then, it wouldn't have any major impact on the company's coal production. With a total of 80 mines, BCCL accounts for about 7% of CIL's production capacity of 461 mt. The Jharkhand government's order covers 22 of those 80 mines.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets open flat with positive bias". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.